FDA retesting found dangerously high yohimbine plus undeclared tadalafil and flibanserin in WAP Sensual Enhancement, adding new cardiovascular, neurologic, and interaction concerns months after an all-lots recall.

The U.S. Food and Drug Administration updated its warning for WAP Sensual Enhancement on August 25, 2026, after testing additional retail samples. FDA laboratory analysis found yohimbine, tadalafil, and flibanserin, none listed on the product label. Most notably, FDA says the product contains dangerously high levels of yohimbine. [1]

The new finding changes the toxicology story. FDA had already reported hidden sildenafil, tadalafil, and flibanserin in WAP on April 6, and all lots were voluntarily recalled in May. The August update adds a distinct concern: unrecognized exposure to high yohimbine alongside two other active drugs. [1] [2]

What Is New in the August 25 Update?

FDA says additional samples obtained from retail stores contained yohimbine, tadalafil, and flibanserin. The agency describes the yohimbine concentration as dangerously high. [1]

FDA warns that high yohimbine exposure may cause severe hypertension, irregular heartbeat, myocardial infarction, gastrointestinal effects, seizures, anxiety, confusion, and tremor. In people with schizophrenia, FDA says it may precipitate mania or psychosis. Risk may be greater with stimulants such as caffeine or ephedra, ADHD medications, monoamine oxidase inhibitors, and certain antidepressants. [1]

These are potential effects of high yohimbine exposure. FDA's August update does not state that WAP caused a myocardial infarction, seizure, psychosis, or any specific number of adverse events.

April Warning, May Recall, August Retesting

The chronology matters.

On April 6, FDA reported sildenafil, tadalafil, and flibanserin in WAP, none declared on the label. [1]

Best Supplements Best Prices then voluntarily recalled all lots of WAP Sensual Enhancement to the consumer level. The company announcement was dated May 11 and FDA published it May 18. [2]

On August 25, FDA updated the original product record after testing additional retail samples. Those samples contained yohimbine, tadalafil, and flibanserin. [1]

The August action is therefore not a new recall. It is a new laboratory update to an already recalled product.

FDA does not mention sildenafil in the August sample findings. That should not be interpreted as proof that sildenafil was absent; the public update does not explain whether it was tested for or simply not reported in those samples.

Why Yohimbine Makes This Story Different

MedicalToxic recently covered hidden sildenafil and tadalafil in FDA Finds Hidden Sildenafil and Tadalafil in Two Sexual-Enhancement Products.

That story centered on hidden PDE-5 inhibitors and nitrate-related hypotension. WAP is clinically different because FDA now identifies dangerously high yohimbine, adding cardiovascular and neurologic toxicity concerns that cannot be reduced to another hidden-PDE-5 warning.

The safety problem is also not ordinary therapeutic drug use. It is that the consumer and treating clinician may be unaware that several active compounds were taken at all.

Hidden Tadalafil Preserves the Nitrate Risk

Tadalafil is a legitimate prescription medication when appropriately used, but undisclosed exposure can create a high-stakes medication-history gap.

Current tadalafil labeling states that tadalafil is contraindicated with organic nitrates because it potentiates their hypotensive effect. Nitrates should not be used within 48 hours after the last tadalafil dose. [3]

That matters if a patient using WAP later presents with chest pain or another condition in which nitrate therapy might be considered. Because FDA does not provide the amount of tadalafil detected in WAP, a pharmaceutical-equivalent dose cannot be inferred from the public findings.

Hidden Flibanserin Adds Hypotension, Syncope, and Sedation Concerns

Flibanserin is also an approved prescription drug when used under appropriate medical supervision. In WAP, the concern is undeclared and unquantified exposure.

Current flibanserin labeling warns that use close in time with alcohol increases the risk of severe hypotension and syncope. Moderate or strong CYP3A4 inhibitors can raise flibanserin concentrations and are contraindicated because of hypotension and syncope risk. The labeling also warns about CNS depression, including somnolence and sedation. [4]

Because flibanserin is not declared on the WAP label, these interactions may not be apparent during medication reconciliation.

One Product, Multiple Hidden Exposures

The August findings show why the phrase “hidden ingredient” can understate the clinical problem.

FDA identified three pharmacologically active compounds in the newer samples:

• Yohimbine: cardiovascular and neurologic toxicity at high exposure;

• Tadalafil: potentially dangerous hypotension with nitrates;

• Flibanserin: hypotension, syncope, sedation, and important interaction risks. [1] [3] [4]

FDA does not publish quantitative tadalafil or flibanserin concentrations, nor does the public notice give the numerical yohimbine level underlying “dangerously high.”

The defensible conclusion is therefore that WAP can create an unrecognized multidrug exposure whose actual dose cannot be reconstructed from the label.

A similar medication-reconciliation problem is documented in Psilocybin Gummies Contaminated with Dangerous Synthetic Compounds, where laboratory testing likewise showed that marketed product identity did not reliably disclose actual active exposures.

What FDA Has—and Has Not—Established

FDA has confirmed that additional WAP samples contained yohimbine, tadalafil, and flibanserin and that none was listed on the label. FDA specifically calls the yohimbine level dangerously high and continues to advise consumers not to purchase or use WAP Sensual Enhancement. [1]

FDA's broader Sexual Enhancement and Energy Product Notifications page cautions that products identified by the agency represent only a small fraction of contaminated products potentially on the market. [5]

The August update does not establish:

• an increase in adverse-event incidence;

• how many consumers used WAP;

• quantitative doses of the hidden compounds;

• that every WAP unit has the same composition;

• that sildenafil was absent from the August samples;

• that WAP caused a myocardial infarction, seizure, or psychiatric event in a reported patient;

• or that a second recall occurred on August 25.

The evidence is best characterized as a laboratory-confirmed hidden multidrug exposure and interaction hazard, not an adverse-event incidence signal.

Practical Implications

Clinicians and pharmacists should ask specifically about nonprescription sexual-enhancement products when evaluating otherwise unexplained severe hypertension, dysrhythmia, tremor, confusion, seizure, hypotension, syncope, sedation, or unexpected drug interactions.

If WAP is reported, the exposure history should not be limited to ingredients printed on the package. FDA has documented multiple undeclared active compounds, while the public data do not provide reliable quantitative dosing information.

FDA advises consumers not to purchase or use WAP and directs consumers and healthcare professionals to report adverse events through MedWatch. [1]

What Is Genuinely New?

The August 25 development is not simply another hidden erectile-dysfunction-drug warning.

FDA had already identified sildenafil, tadalafil, and flibanserin in April, followed by an all-lots recall in May. The genuinely new development is the finding of dangerously high yohimbine together with tadalafil and flibanserin in additional retail samples. [1] [2]

That gives the WAP update a separate MedicalToxic search intent centered on high-yohimbine multidrug toxicity, rather than duplicating the earlier hidden sildenafil/tadalafil story.

Limitations and Remaining Unknowns

FDA has not published the numerical yohimbine concentration, tadalafil or flibanserin dose, the number of consumers exposed, or an adverse-event incidence rate.

The agency also does not state when the additional retail samples were purchased, whether they were inventory already covered by the May recall, or whether every WAP lot had the same composition.

These uncertainties prevent dose-response or incidence claims, but they do not change the laboratory-confirmed finding that the product label failed to disclose multiple active drugs.

Conclusion

FDA's August 25 update materially expands the WAP Sensual Enhancement safety concern.

Additional retail samples contained dangerously high yohimbine plus undeclared tadalafil and flibanserin. The product had already been recalled after earlier testing found sildenafil, tadalafil, and flibanserin. [1] [2]

The central toxicology issue is not that prescribed tadalafil or flibanserin are inherently unsafe. It is hidden, unquantified multidrug exposure: the patient and clinician may be making cardiovascular, neurologic, and medication-interaction decisions without knowing what was actually taken.

References

1. U.S. Food and Drug Administration. (2026, August 25; original notification April 6, 2026). WAP Sensual Enhancement may be harmful due to hidden drug ingredients.

2. U.S. Food and Drug Administration. (2026, May 18). Best Supplements Best Prices Issues Voluntary Nationwide Recall of WAP Sensual Enhancement Capsules Due to Presence of Undeclared Sildenafil, Tadalafil, and Flibanserin.

3. DailyMed, U.S. National Library of Medicine. TADALAFIL tablet.

4. DailyMed, U.S. National Library of Medicine. ADDYI — flibanserin tablet, film coated.

5. U.S. Food and Drug Administration. Sexual Enhancement and Energy Product Notifications.